Chelsea Therapeutics International Ltd

Chelsea Therapeutics International — Technical Presentation (September 2010)

27 slides from Chelsea Therapeutics International's technical presentation, Sep 20, 2010

  1. Slide 1: Northera (droxidopa) Preliminary Findings From Study 301 in Symptomatic NOH

    Slide 1: Northera (droxidopa) Preliminary Findings From Study 301 in Symptomatic NOH

    © 2004-2010 Chelsea Therapeutics, Inc. Northera™ (droxidopa) Preliminary Findings From Study 301 in Symptomatic Neurogenic Orthostatic Hypotension September 2010

  2. Slide 2: Forward-Looking Statement

    Slide 2: Forward-Looking Statement

    Forward-Looking Statement Forward-Looking Statement This presentation is being provided for informational and discussion purposes. This presentation is not intended to provide and should not be relied upon as investment advice or an opinion regarding the appropriateness or suitability of any investm

  3. Slide 3: Northera Phase III Program: NOH

    Slide 3: Northera Phase III Program: NOH

    Northera Phase III Program: NOH Northera Phase III Program: NOH Study 302: Pivotal Proof of Efficacy – Withdrawal Design Study 303: Long-Term Safety Extension to Study – includes long-term efficacy assessment after months Study 301: Pivotal Proof of Efficacy – Induction Design Study 304: Long-Term S

  4. Slide 4: Key Symptomatic Efficacy Outcome Measures

    Slide 4: Key Symptomatic Efficacy Outcome Measures

    Key Symptomatic Efficacy Outcome Measures Key Symptomatic Efficacy Outcome Measures Orthostatic Hypotension Questionnaire: OHQ • Orthostatic Hypotension Symptom Assessment: OHSA Please circle the number on the scale (0-10) that best rates how severe your symptoms from low blood pressure have been on

  5. Slide 5: Study 301: Baseline Diagnoses

    Slide 5: Study 301: Baseline Diagnoses

    Study 301: Baseline Diagnoses Study 301: Baseline Diagnoses Symptomatic, Neurogenic Orthostatic Hypotension Associated with Primary Autonomic Failure, Dopamine -hydroxylase Deficiency & Non-diabetic Autonomic Neuropathies • Diverse patient population with varied & distinct primary diseases • Common

  6. Slide 6: Study 301: Demographic Data

    Slide 6: Study 301: Demographic Data

    Study 301: Demographic Data Study 301: Demographic Data Double Blind Phase Placebo Northera (N=80) (N=82) Gender [N(%)] Male 42 ( 52.5) 42 ( 51.2) Female 38 ( 47.5) 40 ( 48.8) Ethnicity White 75 ( 93.8) 82 (100.0) Black/African-American 1 ( 1.3) Asian 1 ( 1.3) Hispanic/Latino 3 ( 3.8) Age (years) at

  7. Slide 7: Study 301: Trial Design

    Slide 7: Study 301: Trial Design

    Study 301: Trial Design Study 301: Trial Design Titration Stopping Rules: 1.Asymptomatic and >10 mmHG in Standing SBP 2.Sustained SBP 180 mmHg or DBP 110 mmHg 3.Intolerable AEs 4.Maximum Dose of 600mg TID reached Responder Criteria: 1. unit improvement on OHSA item #1 (dizziness); AND 2. mmHg in Sta

  8. Slide 8: Study 301: Optimal Dose Post-Titration

    Slide 8: Study 301: Optimal Dose Post-Titration

    Study 301: Optimal Dose Post-Titration Study 301: Optimal Dose Post-Titration Dose of Northera (mg TID)

  9. Slide 9: Study 301: Broad Symptomatic Benefits

    Slide 9: Study 301: Broad Symptomatic Benefits

    Study 301: Broad Symptomatic Benefits Study 301: Broad Symptomatic Benefits Favors Northera Favors Placebo 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 OHSA OHDAS *** * p 0.05 ** p 0.01 *** p 0.001 ** * * ** *** ** ** ** ** **

  10. Slide 10: Study 301: Change in OHSA Scores

    Slide 10: Study 301: Change in OHSA Scores

    NASDAQ: CHTP Study 301: Change in OHSA Scores Study 301: Change in OHSA Scores Placebo * p 0.05 ** p 0.01 *** p 0.001 *** ** * * Northera

  11. Slide 11: Study 301: Change in OHDAS Scores

    Slide 11: Study 301: Change in OHDAS Scores

    Study 301: Change in OHDAS Scores Study 301: Change in OHDAS Scores Placebo *** ** ** ** Northera

  12. Slide 12: Study 301: Change in Composite Scores

    Slide 12: Study 301: Change in Composite Scores

    Study 301: Change in Composite Scores Study 301: Change in Composite Scores OHQ OHSA OHDAS 0.0 0.5 1.0 1.5 2.0 2.5 Placebo * p 0.05 ** p 0.01 *** p 0.001 ** ** ** Northera

  13. Slide 13: Study 301: Effect of Northera on Standing SBP

    Slide 13: Study 301: Effect of Northera on Standing SBP

    Study 301: Effect of Northera on Standing SBP Study 301: Effect of Northera on Standing SBP Washout R Placebo Northera No Drug Placebo * p 0.05 ** p 0.01 *** p 0.001 ***

  14. Slide 14: Study 301: Effect of Northera on Supine SBP

    Slide 14: Study 301: Effect of Northera on Supine SBP

    Study 301: Effect of Northera on Supine SBP Study 301: Effect of Northera on Supine SBP Washout R Placebo Northera No Drug Placebo * p 0.05 ** p 0.01 *** p 0.001 ***

  15. Slide 15: Study 301: Effect of Northera on Standing SBP

    Slide 15: Study 301: Effect of Northera on Standing SBP

    Study 301: Effect of Northera Study 301: Effect of Northera on Standing SBP on Standing SBP SBP from randomization Supine Standing Placebo Northera *** p 0.001 *** ***

  16. Slide 16: Study 301: No Serious Adverse Events

    Slide 16: Study 301: No Serious Adverse Events

    Study 301: No Serious Adverse Events Study 301: No Serious Adverse Events • Most common adverse events reported: • Headache: 0.0 % placebo, 7.4 % Northera • Falls: 4.3 % placebo, 0.0 % Northera

  17. Slide 17: Apnis

    Slide 17: Apnis

    Apnis Jo pug 0} uoHjeziwopuey wo. abueyD CHELSEA THERAPEUTICS

  18. Slide 18: Study 301: Response in Parkinson's Disease

    Slide 18: Study 301: Response in Parkinson's Disease

    NASDAQ: CHTP Study 301: Response in Parkinson’s Disease Study 301: Response in Parkinson’s Disease 0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 Placebo Northera

  19. Slide 19: Study 302: Parkinson's Response Over Time

    Slide 19: Study 302: Parkinson's Response Over Time

    Weeks of Treatment Study 302: Parkinson’s Response Over Time Study 302: Parkinson’s Response Over Time

  20. Slide 20: Study 306: NOH in Parkinson's Disease

    Slide 20: Study 306: NOH in Parkinson's Disease

    Double-Blind Titration Double-Blind Treatment Study 306: NOH in Parkinson’s Disease Study 306: NOH in Parkinson’s Disease Randomization Visit 2 Up to 2 weeks 8 weeks Visit 1 Visit 3a, 3b, 3c…. Visit 7 2 weeks • Enriched Homogeneous population: 84 PD Patients with NOH • Longer Treatment duration allo

  21. Slide 21: Next Steps: NOH Registration Program

    Slide 21: Next Steps: NOH Registration Program

    Next Steps: NOH Registration Program Next Steps: NOH Registration Program Complete Study 301 Data Analysis Present full data set: American Autonomic Society Annual Meeting, Nov. 2010 Continue Preparations for Rolling NDA Submission to be initiated first half Request Pre-NDA Meeting Complete Study 30

  22. Slide 22: Study 301: Broad Symptomatic Benefits

    Slide 22: Study 301: Broad Symptomatic Benefits

    Study 301: Broad Symptomatic Benefits Study 301: Broad Symptomatic Benefits -0.50 -0.25 0.00 0.25 0.50 0.75 1.00 1.25 1.50 OHSA OHDAS * p 0.05 ** p 0.01 *** p 0.001 * ** *** ** ** * ** ** *** ** ** * * * *

  23. Slide 23: Positioning Northera

    Slide 23: Positioning Northera

    Positioning Northera Positioning Northera Target Profile: Northera™ is used as first line chronic oral therapy in NOH because it is the only drug proven to reduce the physical symptoms of dizziness, lightheadedness, and falling sensations associated with neurogenic orthostatic hypotension by safely

  24. Slide 24: Current Therapeutic Landscape

    Slide 24: Current Therapeutic Landscape

    • Poor Surrogate at Best: Midodrine (ProAmatine®)…alpha agonist: 52,000 patients* • Not approved for symptomatic benefit • Provides constant/undifferentiated pressor effect: equal effect supine vs. standing • Black box warning for supine hypertension…22% at 10 mg. dose • Alpha agonist side effects •

  25. Slide 25: Northera: US Commercial Opportunity

    Slide 25: Northera: US Commercial Opportunity

    • Attractive US Pricing Model: US sales of $300-$375 million within 3-5 years of launch assuming: • Price: $30/day • Compliance: 70% • Limited Sales Force Requirements ~ 85 Sales Reps • 10% of Midodrine Sales Generated by Only 232 Physicians • ~4,000 physicians responsible for 50% of midodrine sales

  26. Slide 26: Study 301: Summary Findings

    Slide 26: Study 301: Summary Findings

    Study 301: Summary Findings Study 301: Summary Findings • Broad Symptomatic & Functional Benefits • Statistically Significant Improvement in Composite OHQ Score vs. Placebo (p=0.003) • Mean decrease of 1.83 units in composite OHQ score • Statistically Significant Improvement in composite OHSA (p=0.0

  27. Slide 27: Looking Ahead....

    Slide 27: Looking Ahead....

    Looking Ahead…. Looking Ahead…. Top-line Results Northera: Study 303 Q2 10 Initiate Northera PIII: NOH Study 306 Q2 10 Interim Analysis Droxidopa PII: Fibromyalgia H2 10 Top-line Results Northera PIII: NOH Study 301 Q3 10 Initiate CH-4051 PII: RA Q4 10 Top-line Results Droxidopa Investigator PII: AD

Source: SEC EDGAR · 8-K filed Sep 20, 2010

More decks from Chelsea Therapeutics International Ltd